Pharmaceutical class: glucagon-like peptide 2 (GLP2) analogue that increases the absorptive surface of the intestinal epithelium. It is indicated for the treatment of short bowel syndrome (SBS-IF) in patients from 1 year of age, in a stable state after the period of intestinal adaptation.